Cardiopulmonary Disorders
The term "Cardiopulmonary Disease" describes a range of conditions affecting the heart and lungs. These organs are closely related, and the problem in one can spill over to another. Exposure to tobacco smoke has long been recognized as an important component of cardiovascular risk. Likewise, minimizing your exposure to tobacco smoke is the most effective way to save you from COPD.
Common types of this condition include:
Chronical bronchitis.
Chronic obstructive pulmonary disease (COPD)
Chronic heart failure.
Emphysema.
Cardiopulmonary disease is the medical term used to describe quite number critical problems that affect the heart and lungs. The two-primary tobacco-associated cardiopulmonary illnesses are Cardiovascular Disease (CVD) and Chronic Obstructive Pulmonary Disorder (COPD). Exposure to tobacco smoke has long been diagnosed as a prominent chance component for Cardiovascular Disease. Similarly minimizing exposure to tobacco smoke is the most effective manner to save you COPD. However, the mechanisms by way of which tobacco toxicants increase the danger of Cardiovascular Disease and result in the onset of COPD are nonetheless unclear. Despite discounts in smoking during the last decade, Cardiovascular Disease and COPD stay the first and second main causes of death among smokers. It is important to keep in mind also that for all of us who dies because of smoking as a minimum 30 people live with a critical smoking-associated illness.
The advent of e-cigarettes and other new tobacco products that deliver nicotine as an aerosol in a variety of solvents raises important new questions regarding the potential risk of cardiopulmonary disease among consumers. The use of this new tobacco product has skyrocketed over the past few years, especially among adolescents, and is expected to completely change the traditional cigarette market in the next decade. These new products deliver nicotine and chemical flavoring aerosols based on propylene glycol and / or glycerin by inhalation.
Related Conference of Cardiopulmonary Disorders
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Cardiopulmonary Disorders Conference Speakers
Recommended Sessions
- Airway and Therapeutic Devices
- Asthma and Allergy
- Cardiopulmonary Disorders
- Case Reports in Pulmonology
- Chronic Bronchitis and Respiratory Diseases
- Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Lung Diseases
- Obstructive sleep apnea
- Pediatric Pulmonology and Critical care
- Pulmonary Diseases and therapeutics
- Pulmonary Hypertension
- Pulmonary Rehabilitation
- Respiratory tract Infections
- Sarcoidosis
- Thoracic
- Tuberculosis
Related Journals
Are you interested in
- Allergy testing and treatment in respiratory diseases - Euro Pulmonology 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Bronchial thermoplasty for asthma management - Euro Pulmonology 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic cough evaluation and treatment strategies - Euro Pulmonology 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and its impact on respiratory health - Euro Pulmonology 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Genetics of respiratory diseases and precision medicine - Euro Pulmonology 2024 (France)
- Imaging techniques in pulmonary medicine - Euro Pulmonology 2024 (France)
- Interstitial lung disease and lung transplant outcomes - Euro Pulmonology 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung cancer and personalized medicine approaches - Euro Pulmonology 2024 (France)
- Lung cancer screening and early detection programs - Euro Pulmonology 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung microbiome and respiratory diseases - Euro Pulmonology 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Non-invasive ventilation techniques and outcomes - Euro Pulmonology 2024 (France)
- Occupational asthma and work-related respiratory diseases - Euro Pulmonology 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pulmonary arterial hypertension diagnosis and management - Euro Pulmonology 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary drug delivery systems and innovations - Euro Pulmonology 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary edema pathophysiology and treatment - Euro Pulmonology 2024 (France)
- Pulmonary embolism diagnosis and management - Euro Pulmonology 2024 (France)
- Pulmonary rehabilitation in critically ill patients - Euro Pulmonology 2024 (France)
- Pulmonary sarcoidosis diagnosis and treatmen - Euro Pulmonology 2024 (France)
- Respiratory failure management in ICU patients - Euro Pulmonology 2024 (France)
- Respiratory syncytial virus updates and management - Euro Pulmonology 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)